Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article (171)

Advertisement

Research Article Free access | 10.1172/JCI107675

Effects of Alterations of Plasma Free Fatty Acid Levels on Pancreatic Glucagon Secretion in Man

John E. Gerich, Maurice Langlois, Victor Schneider, John H. Karam, and Claudio Noacco

1Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Find articles by Gerich, J. in: JCI | PubMed | Google Scholar

1Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Find articles by Langlois, M. in: JCI | PubMed | Google Scholar

1Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Find articles by Schneider, V. in: JCI | PubMed | Google Scholar

1Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Find articles by Karam, J. in: JCI | PubMed | Google Scholar

1Metabolic Research Unit and Department of Medicine, University of California, San Francisco, California 94143

Find articles by Noacco, C. in: JCI | PubMed | Google Scholar

Published May 1, 1974 - More info

Published in Volume 53, Issue 5 on May 1, 1974
J Clin Invest. 1974;53(5):1284–1289. https://doi.org/10.1172/JCI107675.
© 1974 The American Society for Clinical Investigation
Published May 1, 1974 - Version history
View PDF
Abstract

The present investigation was undertaken to ascertain whether alterations in plasma free fatty acids (FFA) affect pancreatic glucagon secretion in man since FFA have been reported to influence pancreatic alpha cell function in other species. Elevation of plasma FFA from a mean (±SE) basal level of 0.478±0.036 mM to 0.712±0.055 mM after heparin administration caused plasma glucagon levels to fall approximately 50%, from a basal value of 122±15 pg/ml to 59±14 pg/ml (P < 0.001). Lowering of plasma FFA from a basal level of 0.520±0.046 mM to 0.252±0.041 mM after nicotinic acid administration raised plasma glucagon from a basal level of 113±18 pg/ml to 168±12 pg/ml (P < 0.005). Infusion of glucose elevated plasma glucose levels to the same degree that heparin raised plasma FFA levels. This resulted in suppression of plasma glucagon despite the fact that plasma FFA levels also were suppressed. Glucagon responses to arginine were diminished after elevation of plasma FFA (P < 0.01) and during infusion of glucose (P < 0.01). Diminution of plasma FFA by nicotinic acid did not augment glucagon responses to arginine.

These results thus demonstrate that rather small alterations in plasma FFA within the physiologic range have a significant effect on glucagon secretion in man. Although the effects of glucose appear to predominate over those of FFA, alterations in plasma FFA may nevertheless exert an important physiologic influence over human pancreatic alpha cell function, especially in the postabsorptive state.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 1284
page 1284
icon of scanned page 1285
page 1285
icon of scanned page 1286
page 1286
icon of scanned page 1287
page 1287
icon of scanned page 1288
page 1288
icon of scanned page 1289
page 1289
Version history
  • Version 1 (May 1, 1974): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article (171)

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts